Systematic (IUPAC) name
N,N-dimethyl-2-[(2-methylphenyl)- phenyl-methoxy]-ethanamine
Clinical data
Trade names Invagesic
AHFS/Drugs.com monograph
MedlinePlus a682162
Pregnancy cat. B2(AU) C(US)
Legal status OTC (CA) POM (UK) -only (US)
Routes Oral, intravenous, intramuscular
Pharmacokinetic data
Bioavailability 90%
Protein binding 95%
Metabolism Hepatic demethylation
Half-life 13-20 hours[1]
Excretion Renal and biliary
CAS number 83-98-7 YesY
ATC code M03BC01 N04AB02
PubChem CID 4601
DrugBank APRD00097
ChemSpider 4440 YesY
KEGG D08305 YesY
Chemical data
Formula C18H23NO 
Mol. mass 269.381 g/mol
SMILES eMolecules & PubChem
 N(what is this?)  (verify)

Orphenadrine (sold under the brand names: Norflex, Mephenamin, Disipal, Banflex, Flexon, Biorphen, Brocasipal, Dolan, Norgesic and others) is an anticholinergic drug of the ethanolamine antihistamine class with prominent CNS and peripheral actions used to treat painful muscle spasms, other similar conditions, as well as the treatment of some aspects of Parkinson's Disease. It is closely related to diphenhydramine. Therefore, it is related to other drugs used for Parkinson's like benztropine and trihexyphenidyl, and it is also structurally related to nefopam,[2] which is a centrally-acting yet non-opioid analgesic. The combination of anticholinergic effects and CNS penetration make orphenadrine useful for pain of all etiologies, including pain from: radiculopathy, muscle pain, headaches, and many other types. Some patients report that it feels like orphenadrine and similar drugs help both NSAIDs and opioids find the pain. Orphenadrine has approximately 58% of the anticholinergic potency of atropine at equivalent doses.

Orphenadrine is most often used against pain and muscle spasm of various etiologies including lumbago, sciatica, and injury. It is quite useful against allergic symptoms and other histamine-related effects, such as those from hay fever, other allergies, and histamine release from many opioid analgesics. Where available for prescription compounding, orphenadrine can also be prepared for topical administration and works slightly better than diphenhydramine for this purpose.

The orphenadrine salt used for Parkinsonism is the hydrochloride, whereas the muscle relaxant tablet are the citrate. The manufacturers' descriptions of orphenadrine indicate that the salts are not interchangeable; one reason may be that the citrate can be irritating when injected.

Euphoria is an effect reported by many patients and orphenadrine has been investigated for use against depression, as first reported in June 1958 in the American Journal of Psychiatry.[3]

Like many first-generation antihistamines and chemically-similar anticholinergics, orphenadrine can also cause excitement and insomnia, particularly in children and the elderly.

Orphenadrine also works on smooth muscle in a manner identical to that of dicyclomine, brand name Bentyl, and will impact Irritable Bowel Syndrome in a similar fashion.



This drug was first synthesised in the late 1940s in Europe and the citrate and hydrochloride were both patented in the United States by Parke-Davis in July 1951. Currently, orphenadrine preparations are made in the United States and Canada by Parke-Davis and other companies including 3M. Known as Disipal, orphenadrine HCl was advertised by the Riker company for Parkinsonism, low back pain, and having a useful anti-depressant effect which helps in treating such conditions -- http://www.decodog.com/inven/MD/md30554.jpg


Orphenadrine is a methylated derivative of diphenhydramine. Common brand names of diphenhydramine include: Benadryl, Sominex, Nytol, etc.), and thus indicates orphenadrine belongs to the ethanolamine family of antihistamines. It is produced by reacting dimethylaminoethanol with 2-methylbenzhydryl chloride. The 2-methylbenzhydryl chloride can be formed via a Grignard reaction. The free base has a molecular weight of 269.38 and an empirical formula of C18H23NO. The molecular weight of orphenadrine hydrochloride is 305.85, and 461.50 for the citrate.


Orphenadrine is known to have the following pharmacology:


Orphenadrine is used to treat muscle injuries, skeletal muscle tension, rigidity secondary to afflictions such prolapsed discs, and degenerative soft tissue disease especially in the lower back, neck, and joints. It is used to treat other causes of muscle spasms to potentiate the action of opioid analgesics against moderate to severe neuropathic pain, and it is also used to treat Parkinson's disease.

Orphenadrine is also a component of various preparations for use against headaches of various types especially tension and histamine headaches. It is also helpful in many cases of fibromyalgia.

The effect on neuropathic pain, which is also in many cases generated by cyclobenzaprine (Flexeril), atropine, scopolamine, hyoscyamine, trazodone, many first-generation antihistamines, and chemically related drugs like dicyclomine, a.k.a. dicycloverine, (Bentyl), trihexyphenidyl (Artane), first-generation tricyclic antidepressants such as amitriptyline, and other similar drugs, are said by many patients to seem to "help the painkillers find the pain".[citation needed]A direct analgesic effect of orphenadrine comes from relaxing painful muscle spasms as well as central antimuscarinic (atropine-like anticholinergic, see below) action and possibly its local anaesthetic effects.

The adjuvant analgesic effect of orphenadrine is neither antagonised nor directly duplicated by some other drugs used for this purpose, such as baclofen (Lioresal), clonidine (Catapres), gabapentin (Neurontin), and others. Therefore, the effects are largely additive if used in combination (same goes for side effects, however). Such medication protocols need close monitoring by a physician especially when other centrally-acting drugs are being used to treat the pain.[citation needed]Cyclobenzaprine, tricyclic anti-depressants, and antihistamines do have additive side effects. However, there is usually little improvement in the clinically desired effects in that they duplicate and compete with each other in this respect.[citation needed]

Orphenadrine can be used in protocols for treating chronic and/or recurring pain as an alternative to gabapentin (Neurontin) as an adjuvant analgesic for management of chronic pain with a neuropathic component amongst those who cannot tolerate the side effects of gabapentin. This is also the case for patients for whom duloxetine (Cymbalta) is contraindicated. Orphenadrine has fewer side effects than many first-generation anti-depressants, cyclobenzaprine, trazadone, clonidine, and other drugs used in chronic pain states.[citation needed]


The citrate salt of orphenadrine is available as Norflex, Banflex, Flexon, and X-Otag, and the hydrochloride salt is available as Disipal and Mephenamin.

In the United States and Canada, orphenadrine citrate is supplied as 100 mg controlled-release tablets, 100 mg immediate-release tablets, and 60 mg immediate-release tablets. Orphenadrine hydrochloride is supplied as 50 and 60 mg tablets, a 10 mg/ml oral solution, and 30 mg/ml solution for injection.

Orphenadrine is often available mixed with aspirin, paracetamol Anarex, ibuprofen, caffeine, and/or codeine in many places. All orphenadrine preparations require a prescription in the United States, but various oral forms are sold over the counter in Canada. Orphenadrine is also available by prescription in many European and Pacific Rim countries (including Australia). In Belgium, Mexico and Canada single-ingredient and combination products are available over the counter. It is also available over the counter in the Philippines and Thailand as Norgesic (35 mg Orphenadrine Citrate/450 mg Paracetamol) and Norgesic Forte (50 mg Orphenadrine Citrate/650 mg Paracetamol) from 3M Pharmaceuticals. Orphenadrine is not available at this time in Japan, Slovenia, Croatia, China, France and Spain.

Dosage and delivery

The muscle-relaxant and analgesic dose of orphenadrine is 100 mg when it is a (theoretical) 12-hour extended release tablet; or 60 to 100 mg every 8 hours in the immediate-release form. When compared with extended release tablets of other drugs, Norflex extended-release tablets more frequently than not require dosing every six or eight hours. It is not clear if the extended-release form of orphenadrine is more effective on a milligram basis than the immediate-release formulations.

The dose to be used in therapy for Parkinson's Disease is 60 mg via the oral, intramuscular, or intravenous route. According to patients for both muscle spasm and Parkinson's Disease, the alternative routes for administration via the mouth (sublingual or buccal) or other transmucosal routes do not appear to impart any therapeutic advantage, and this would seem to include the rectal route as well.

Side effects

Orphenadrine has the side effects of the other common antihistamines in large part. Stimulation is somewhat more common than with other related antihistamines, and is especially common in the elderly. Common side effects include: dry mouth, dizziness, drowsiness, restlessness, insomnia, constipation, urine retention, orthostatic hypotension, and euphoria. The drowsiness and similar side effects tend to resolve within the first three to seven days of therapy. The euphoria is slight to moderate and subjectively different from that of both opioids and carisoprodol. Also, the somewhat cleaner side effect profile than cyclobenzaprine increases the therapeutic usefulness of the euphorigenic and anxiolytic effects.


The cautions and contraindications that apply to other antihistamines in its group apply. Dry mouth should be treated to prevent trouble with teeth. One should avoid driving and operating heavy machinery until such time as the effect is known. Constipation is possible but usually less severe than that caused by opioids. Aside from brief rebound stiffness in some patients, orphenadrine does not produce detectable cessation symptoms after therapy is discontinued.


  1. ^ Labout JJ, Thijssen C, Keijser GG, Hespe W. "Difference between single and multiple dose pharmacokinetics of orphenadrine hydrochloride in man." European Journal of Clinical Pharmacology. 1982;21(4):343-50. PubMed
  2. ^ Fernández-Sánchez MT, Díaz-Trelles R, Groppetti A, et al. (2002). "Nefopam, an analogue of orphenadrine, protects against both NMDA receptor-dependent and independent veratridine-induced neurotoxicity". Amino acids 23 (1–3): 31–6. doi:10.1007/s00726-001-0106-6. PMID 12373515. 
  3. ^ ROBITSCHER JB, PULVER SE (June 1958). "Orphenadrine in the treatment of depression; a preliminary study". The American journal of psychiatry 114 (12): 1113–5. PMID 13533653. http://ajp.psychiatryonline.org/cgi/pmidlookup?view=long&pmid=13533653. 
  4. ^ Syvälahti EK, Kunelius R, Laurén L (February 1988). "Effects of antiparkinsonian drugs on muscarinic receptor binding in rat brain, heart and lung". Pharmacology & Toxicology 62 (2): 90–4. doi:10.1111/j.1600-0773.1988.tb01852.x. PMID 3353357. 
  5. ^ Rumore MM, Schlichting DA (February 1985). "Analgesic effects of antihistaminics". Life Sciences 36 (5): 403–16. doi:10.1016/0024-3205(85)90252-8. PMID 2578597. 
  6. ^ Kornhuber J, Parsons CG, Hartmann S, et al. (1995). "Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: binding and patch clamp studies". Journal of Neural Transmission. General Section 102 (3): 237–46. doi:10.1007/BF01281158. PMID 8788072. 
  7. ^ Pubill D, Canudas AM, Pallàs M, et al. (March 1999). "Assessment of the adrenergic effects of orphenadrine in rat vas deferens". The Journal of Pharmacy and Pharmacology 51 (3): 307–12. doi:10.1211/0022357991772303. PMID 10344632. http://openurl.ingenta.com/content/nlm?genre=article&issn=0022-3573&volume=51&issue=3&spage=307&aulast=Pubill. 
  8. ^ Desaphy JF, Dipalma A, De Bellis M, et al. (April 2009). "Involvement of voltage-gated sodium channels blockade in the analgesic effects of orphenadrine". Pain 142 (3): 225–35. doi:10.1016/j.pain.2009.01.010. PMID 19217209. http://linkinghub.elsevier.com/retrieve/pii/S0304-3959(09)00039-6. 
  9. ^ Scholz EP, Konrad FM, Weiss DL, et al. (December 2007). "Anticholinergic antiparkinson drug orphenadrine inhibits HERG channels: block attenuation by mutations of the pore residues Y652 or F656". Naunyn-Schmiedeberg's Archives of Pharmacology 376 (4): 275–84. doi:10.1007/s00210-007-0202-6. ISBN 0021000702026. PMID 17965852. 

External links